The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors

Oncology

Volumn 71, Issue 5-6, 2007, Pages 437-445

  Morita, Shinji ^a   Iida, Satoru ^a   Kato, Keiji ^a   Takagi, Yoko ^a   Uetake, Hiroyuki ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

5 Aza 2 deoxycytidine; 5 Fluorouracil; Chemosensitivity; CpG island; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEATH ASSOCIATED PROTEIN KINASE; FLUOROURACIL; PROTEIN P14; PROTEIN P16;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CPG ISLAND; DRUG EFFECT; DRUG POTENTIATION; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; HUMANS; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P14ARF; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35348832560     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107110     Document Type: Article

References (38)

1. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J: Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-1036.
2. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H: p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001;20:571-580.
3. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269.
4. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanism of action and clinical strategies. Nat Rev Cancer 2003;3:330-338.
5. Tillman DM, Petak I, Houghton JA: A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5:425-430.
6. Adachi Y, Taketani S, Oyaizu H, Ikebukuro K, Tokunaga R, Ikehara S: Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-γ through caspase 3 and caspase 8. Int J Oncol 1999;6:1191-1196.
7. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
8. Jubb AM, Bell SM, Quirke P: Methylation and colorectal cancer. J Pathol 2001;195:111-134.
9. Esteller M, Herman JG: Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumors. J Pathol 2002;196:1-7.
10. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-5740.
11. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
12. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93.
13. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-11801.
14. Christman JK: 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-5495.
15. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM: The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 1987:23:1921-1924.
16. Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB: 5-aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer: phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol 1992:3:399-400.
17. Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, et al: A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997;11(suppl 1):S24-S27.
18. Schwartsmann G, Fernandes MS, Schaan MD, Moschen M, Gerhardt LM, Di Leone L, Loitzembauer B, Kalakun L: Decitabine (5-aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 1997;11(suppl 1):S28-S31.
19. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-962.
20. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M: Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997;11:1617-1620.
21. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR: Evaluation of a 7-day continuous intravenous infusion of decitabine; inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005;23:3897-3905.
22. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640.
23. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586.
24. Goffin J, Eisenhauer E: DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002;13:1699-1716.
25. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-6044.
26. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-1121.
27. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73.
28. INK4a methylation and p53 mutational status. Cancer Res 2000;60:129-133.
29. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa JP: P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 2003;124:626-633.
30. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
31. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001;3:1-7.
32. Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 2001;59:751-757.
33. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY: Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003;100:2420-2425.
34. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM: TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000;60:6236-6242.
35. Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K: Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005;11:1021-1027.
36. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K, Nishiyama M: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004;10:7100-7107.
37. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, Francoual M, Formento P, Renee N, Chamorey E, Bourgeon A, Seitz JF, et al: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002;20:2832-2843.
38. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.